Abstract 1447P
Background
Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- radiation +/- immune checkpoint inhibitors (ICI) may benefit from a second-line CT mostly based on paclitaxel and irinotecan but no randomized trial compared these regimens.
Methods
OESIRI-PRODIGE 62 is a multicenter, open-label, randomized phase II trial evaluating efficacy and safety of nanoliposomal irinotecan (Nal-IRI) + 5FU versus paclitaxel as second-line CT in mESCC. The primary endpoint was percentage of pts alive at 9 months (OS) (H0=40% and H1=60%). With α 5%, power 85% and 5% of pts lost to follow-up, 53 pts per arm (n=106) were required. Secondary endpoints were progression-free survival (PFS), overall response rate (ORR), safety and quality of life (QoL).
Results
Between March 2019 and July 2023, 106 pts were randomized. Median age was 65.6 years, 83.0% men and 29.2%/58.5%/12.3% ECOG PS 0/1/2. Most pts had lymph node (68.3%), lung (52.9%) and liver metastases (24.8%). As prior treatment, 48.6% had chemoradiation, 41.9% CT alone and 9.5% CT plus ICI. The OS rate at 9 months was 34.0% [90%CI: 22.9-46.5] and 39.2% [90%CI: 27.7-51.7] in 5FU Nal-IRI and paclitaxel arms, respectively. Primary endpoint was not met. Median PFS were 2.4 [95%CI: 2.1-3.6] and 2.1 [95%CI: 1.9-3.3] months, disease control rates 47.8% and 40.4%, and median OS 7.1 [95%CI: 5.2-8.3] and 6.6 [95%CI: 4.8-10.3] months, respectively. 51.0% and 38.5% of pts experienced at least one grade 3-4 adverse events related to the treatment (neuropathy: 2.0 vs 7.7%, leucopenia: 6.1 vs 15.4%, diarrhea: 16.3% vs 0% and vomiting: 10.2 vs 0%), in 5FU Nal-IRI and paclitaxel arms, respectively. Two toxic deaths were observed in 5FU Nal-IRI arm. Treatment stop and dose reduction for toxicity were observed in 10.4% versus 3.9%, and 77.8% versus 83.3% in 5FU Nal-IRI and paclitaxel arms, respectively. 63.0% and 48.3% had a deterioration in QoL (loss of more than 5 points of the EORTC-QLQC30).
Conclusions
OESIRI-PRODIGE 62 trial showed low efficacy of paclitaxel and 5FU Nal-IRI in 2nd line treatment for mESCC patients, though paclitaxel provided better safety profile.
Clinical trial identification
NCT03719924.
Editorial acknowledgement
Legal entity responsible for the study
Fédération Francophone de Cancérologie Digestive.
Funding
Servier.
Disclosure
D. Tougeron: Financial Interests, Personal, Advisory Board: AstraZeneca, Sanofi, Amgen, MSD, Roche, Servier, Pierre Fabre, BMS, Bayer; Non-Financial Interests, Member of Board of Directors: Federation Francophone de Cancerologie Digestive. C. Poisson Ligeza: Financial Interests, Personal, Invited Speaker: Servier. V. Bourgeois: Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Principal Investigator: AstraZeneca; Non-Financial Interests, Personal, Non financial benefits, Congress Invitation: Merck, Amgen, Viatris, Pierre Fabre, MSD. V. Jestin: Financial Interests, Personal, Other, invitation à une formation: Novartis, MSD, Merck; Financial Interests, Personal, Other, contribution organisation réunion scientifique: Leopharma; Financial Interests, Personal, Invited Speaker: Sanofi. O. Dubreuil: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Sanofi, Pierre Fabre, Servier, MSD, AstraZeneca. O. Bouche: Financial Interests, Personal, Advisory Board: Amgen, Merck, Apmonia Therapeutics, Deciphera, Astellas, Takeda; Financial Interests, Personal, Invited Speaker: Servier, Pierre Fabre, Bayer. A. Lievre: Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, BMS, Esteve, Pierre Fabre Oncologie, Servier, Viatris; Financial Interests, Personal, Advisory Board: Astellas, BMS, Bayer, Servier; Financial Interests, Institutional, Research Grant, RePERSO trial: Bayer; Financial Interests, Institutional, Coordinating PI, SOCRATE trial (FFCD promotion): Lilly; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Bayer, Incyte, Lilly; Non-Financial Interests, Other, Travel and meeting registration: Bayer, Pierre Fabre, Servier, Viatris. F. Di Fiore: Financial Interests, Personal, Advisory Board: Amgen, BMS; Financial Interests, Personal, Invited Speaker: AstraZeneca, Sanofi, Bayer, Ipsen, Merck, Roche, Servier, MSD, Pierre Fabre, Takeda, Janssen. T. Lecomte: Financial Interests, Personal, Advisory Board: Sanofi, Merck Serono, Servier, Amgen, Ipsen, Pierre Fabre, AstraZeneca, Deciphera, Bayer. C. Lepage: Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Invited Speaker: Amgen, Pierre Fabre, Ipsen. V. Hautefeuille: Financial Interests, Personal, Invited Speaker: Novartis, Merck, Amgen; Financial Interests, Personal, Advisory Board: AAA, Ipsen, Pierre Fabre; Financial Interests, Institutional, Invited Speaker: Deciphera, Esteve. All other authors have declared no conflicts of interest.
Resources from the same session
1456P - First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Presenter: Tianshu Liu
Session: Poster session 18
1457P - Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy
Presenter: Guangyu Yao
Session: Poster session 18
1458P - Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer
Presenter: Shunyu Zhang
Session: Poster session 18
Resources:
Abstract
1459P - Long-term management and outcomes in gastroesophageal cancer in Norway
Presenter: Aleksander Kolstad
Session: Poster session 18
1460P - Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer
Presenter: Denice Kamp
Session: Poster session 18
1462P - A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION)
Presenter: Bin Li
Session: Poster session 18
1463P - The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Presenter: Sebastiaan Siegerink
Session: Poster session 18
1464P - Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Presenter: Brian Housman
Session: Poster session 18
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18